ASGCT 2021 | Novel oncolytic Ad6 vectors for cancer therapy

Margarita Romanenko, PhD, University of Minnesota, Minneapolis, MN, describes a novel adenovirus serotype 6 (Ad6) oncolytic vector currently being investigated for the potential treatment of different cancer types such as glioblastoma and breast cancer. With the aim of enhancing anti-tumor efficacy, a recombinant Ad6 vector was developed with the tumor-specific human telomerase reverse transcriptase (hTERT) promoter and the expression of the human granulocyte macrophage colony-stimulating factor (GMCSF). Further preclinical study is required to further evaluate the potential of the Ad6-hTERT-GMCSF vector as an oncolytic vector and a vaccine. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.